Literature DB >> 10464671

Ashkenazi Jewish population frequency of the Bloom syndrome gene 2281 delta 6ins7 mutation.

B B Roa1, C V Savino, C S Richards.   

Abstract

Bloom syndrome is an autosomal recessive disorder characterized clinically by small size, sun-sensitive facial erythema, and immunodeficiency, and cytogenetically by increased chromosome breakage and sister chromatid exchange. Genomic instability renders Bloom syndrome patients at elevated risk for multiple cancers. Bloom syndrome occurs most commonly in the Ashkenazi Jewish population due to an apparent founder effect. The BLM gene on chromosome 15q26.1 was identified to encode a RecQ DNA helicase. Multiple mutations were identified, with Ashkenazi Jewish Bloom syndrome patients almost exclusively homozygous for a complex frameshift mutation (6-bp deletion/7-bp insertion at BLM nucleotide 2,281). This molecular genetic study seeks to verify the Ashkenazi Jewish carrier frequency of the BLM 2281 delta 6ins7 allele using semiautomated allele-specific oligonucleotide (ASO) analysis. Anonymized DNA samples from 1,016 Ashkenazi Jewish individuals and 307 non-Jewish individuals were screened. Ten Ashkenazi heterozygote carriers for the 2281 delta 6ins7 mutation were identified, giving a carrier frequency estimate of 0.98%, or approximately 1 carrier out of 102 individuals in the Ashkenazi Jewish population. These results are consistent with previous estimates, and combining our findings with the published molecular data collectively yields an Ashkenazi Jewish carrier frequency of approximately 1 in 104. Given its high population frequency and detection rate among Ashkenazi Jewish patients, the blmAsh mutation constitutes an appropriate addition to screening panels for Ashkenazi Jewish disease testing.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10464671     DOI: 10.1089/gte.1999.3.219

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  9 in total

1.  Nemaline myopathy in the Ashkenazi Jewish population is caused by a deletion in the nebulin gene.

Authors:  Sylvia L Anderson; Josef Ekstein; Mary C Donnelly; Erin M Keefe; Nicole R Toto; Lauretta A LeVoci; Berish Y Rubin
Journal:  Hum Genet       Date:  2004-06-23       Impact factor: 4.132

Review 2.  Human pyruvate kinase M2: a multifunctional protein.

Authors:  Vibhor Gupta; Rameshwar N K Bamezai
Journal:  Protein Sci       Date:  2010-11       Impact factor: 6.725

3.  First Two Cases of Bloom Syndrome in Russia: Lack of Skin Manifestations in a BLM c.1642C>T (p.Q548X) Homozygote as a Likely Cause of Underdiagnosis.

Authors:  Evgeny N Suspitsin; Farida I Sibgatullina; Lydia V Lyazina; Evgeny N Imyanitov
Journal:  Mol Syndromol       Date:  2017-01-17

4.  Complex SNP-based haplotypes in three human helicases: implications for cancer association studies.

Authors:  Dimitra Trikka; Zhe Fang; Alex Renwick; Sally H Jones; Ranajit Chakraborty; Marek Kimmel; David L Nelson
Journal:  Genome Res       Date:  2002-04       Impact factor: 9.043

Review 5.  Bloom's Syndrome: Clinical Spectrum, Molecular Pathogenesis, and Cancer Predisposition.

Authors:  Christopher Cunniff; Jennifer A Bassetti; Nathan A Ellis
Journal:  Mol Syndromol       Date:  2016-11-05

6.  Bloom syndrome: multiple retinopathies in a chromosome breakage disorder.

Authors:  R B Bhisitkul; M Rizen
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

7.  Genetic predispositions to childhood leukemia.

Authors:  Elliot Stieglitz; Mignon L Loh
Journal:  Ther Adv Hematol       Date:  2013-08

8.  Bloom syndrome with myelodysplastic syndrome that was converted into acute myeloid leukaemia, with new ophthalmologic manifestations: the first report from Syria.

Authors:  Sara Aljarad; Ahmad Alhamid; Ahmad Rami Rahmeh; Abdelaziz Alibraheem; Abdulsamad Wafa; Walid Alachkar; Ziad Aljarad; Ghasan Aziz
Journal:  Oxf Med Case Reports       Date:  2018-11-05

Review 9.  Rare Genetic Diseases with Defects in DNA Repair: Opportunities and Challenges in Orphan Drug Development for Targeted Cancer Therapy.

Authors:  Sonali Bhattacharjee; Saikat Nandi
Journal:  Cancers (Basel)       Date:  2018-09-01       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.